Loading...
•
Mar 31, 2021
Baxter Q1 2021 Earnings Report
Reported a 5% increase in first-quarter revenue and a decline in both U.S. GAAP EPS and Adjusted EPS.
Key Takeaways
Baxter International Inc. reported a 5% increase in first-quarter revenue, driven by Acute Therapies and BioPharma Solutions. The company's U.S. GAAP earnings per share (EPS) declined 9%, and adjusted EPS decreased by 7%. Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis.
First-quarter revenue increased 5% on a reported basis.
U.S. GAAP earnings per share (EPS) declined 9%.
Adjusted EPS declined 7%.
Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Baxter expects full-year 2021 sales growth of 8% to 9% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis. The company expects U.S. GAAP earnings of $2.85 to $2.93 per diluted share and adjusted earnings of $3.47 to $3.55 per diluted share.
Positive Outlook
- Full-year 2021 sales growth of 8% to 9% on a reported basis.
- Full-year 2021 sales growth of 5% to 6% on a constant currency basis.
- Full-year 2021 sales growth of 4% to 5% on an operational basis.
- Full-year U.S. GAAP earnings of $2.85 to $2.93 per diluted share.
- Full-year adjusted earnings of $3.47 to $3.55 per diluted share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...